Proceedings - Clinical Pharmacology - Veterinary Healthcare
  • SEARCH:

ADVERTISEMENT

Proceedings - Clinical Pharmacology
Source: CVC IN SAN DIEGO PROCEEDINGS

Drug labels: friend or foe? (Proceedings)

November 1, 2010

Today's drug package insert (DPI) can be a powerful ally in the selection and judicious use of a drug. The information that it provides might be categorized as either Product Description, Product Efficacy or Product Safety with some overlap among the categories.

Source: CVC IN SAN DIEGO PROCEEDINGS

Antithrombotics: new drugs, new doses? (Proceedings)

November 1, 2010

Thromboembolic agents are indicated for a variety of conditions, ranging from disseminated intravascular coagulation to pulmonary thromboembolism in both dogs and cats. The selection of appropriate thromboembolic therapy will depend on the underlying condition and the goal of treatment.

Source: CVC IN SAN DIEGO PROCEEDINGS

Safe use of cytotoxic drugs (Proceedings)

November 1, 2010

In the therapy of neoplastic infections with cytotoxic drugs, there is little basis for the selective killing of the abnormal cells as opposed to the healthy cells in the body. There are only a few known differences in receptors and metabolism that are suitable drug targets at the present time.

Source: CVC IN SAN DIEGO PROCEEDINGS

Chihuahuas to mastiffs: therapeutics and body size (Proceedings)

November 1, 2010

Small animal practitioners are well aware that "cats are not small dogs". However, are small dogs just miniaturized versions of their larger brothers and sisters? What about the effect of breed on therapeutics? The incredible diversity of dog breeds presents veterinarians with problems and opportunities inherent to the medical care for such a highly variable species.

Source: CVC IN SAN DIEGO PROCEEDINGS

A case-based approach to therapeutic drug monitoring: increasing the likelihood of success (Proceedings)

November 1, 2010

The success of any fixed dosing regimen most often is based on the patient's clinical response to the drug. Fixed dosing regimens are designed to generate plasma drug concentrations (PDC) within a therapeutic range, ie, achieve the desired effect while avoiding toxicity.

Source: CVC IN SAN DIEGO PROCEEDINGS

Chondroprotective agents: Do they work? (Proceedings)

November 1, 2010

Chondroprotective agents are available as injectable and oral formulations. The injectable formulations are classified as drugs and are regulated by the FDA. The present discussion will focus on the more nebulous branch of chondroprotective agents, the nutraceuticals.

Source: CVC IN SAN DIEGO PROCEEDINGS

Therapy of CHF: choices and controversies (Proceedings)

November 1, 2010

Congestive heart failure (CHF) is not a primary disease; rather it is the manifestation of the failing heart that arises from neurohumoral compensation. The primary problems that underlie CHF can be diverse, but commonly involve myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM) in dogs and hypertrophic cardiomyopathy in cats.

Source: CVC IN SAN DIEGO PROCEEDINGS

Nutraceuticals: myth or must? (Proceedings)

November 1, 2010

Close to 30% of pet owners have used or considered the use of novel ingredients (eg, nutraceuticals and herbs/botanicals) in their animals. In the USA, approximately 90% of veterinarians sell some type of novel ingredient and the current market of veterinary novel ingredients is between $20 and $50 million per year.

Source: CVC IN SAN DIEGO PROCEEDINGS

Designing a dosing regimen based on time vs. concentration dependency: a dynamic challenge (Proceedings)

November 1, 2010

Dosing regimens for antimicrobials exemplify the integration of pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). For antimicrobial therapy, the "body" is the microbe.

ADVERTISEMENT

Click here